Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα

The oncolytic adenovirus (Ad) is currently being advanced as a promising antitumor remedy as it selectively replicates in tumor cells and can transfer and amplify therapeutic genes. Interleukin (IL)-12 induces a potent antitumor effect by promoting natural killer (NK) cell and cytotoxic T cell activities. IL-18 also augments cytotoxicity of NK cells and proliferation of T cells. This effect further enhances the function of IL-12 in a synergistic manner. Therefore, we investigated for the first time an effective cancer immunogene therapy of syngeneic tumors via intratumoral administration of oncolytic Ad co-expressing IL-12 and IL-18, RdB/IL-12/IL-18. Intratumoral administration of RdB/IL-12/IL-18 improved antitumor effects, as well as increased survival, in B16-F10 murine melanoma model. The ratio of T-helper type 1/2 cytokine as well as the levels of IL-12, IL-18, interferon-γ and granulocyte–macrophage colony-stimulating factor was markedly elevated in RdB/IL-12/IL-18-treated tumors. Mice injected with RdB/IL-12/IL-18 also showed enhanced cytotoxicity of tumor-specific immune cells. Consistent with these results, immense necrosis and infiltration of NK cells, as well as CD4+ and CD8+ T cells, were observed in RdB/IL-12/IL-18-treated tumor tissues. Importantly, tumors treated with RdB/IL-12/IL-18 showed an elevated number of T cells expressing IL-12Rβ2 or IL-18Rα. These results provide a new insight into therapeutic mechanisms of IL-12 plus IL-18 and provide a potential clinical cancer immunotherapeutic agent for improved antitumor immunity.

• Publication year

  2011

• Venue

  Gene Therapy

• Publication date

  2011-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/gt.2011.37PMID 21451575PMCID 3169807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Secretion of interferon‐γ by human macrophages demonstrated at the single‐cell level after costimulation with interleukin (IL)‐12 plus IL‐18

  2009cited by this paper
• Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL

  2009cited by this paper
• Cytokine gene‐mediated immunotherapy: Current status and future perspectives

  2009cited by this paper
• E1A- and E1B-Double Mutant Replicating Adenovirus Elicits Enhanced Oncolytic and Antitumor Effects

  2007cited by this paper
• Recombinant interleukin‐12 and interleukin‐18 antitumor therapy in a guinea‐pig hepatoma cell implant model

  2007cited by this paper
• Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model

  2006cited by this paper
• Mycobacteria induce IFN-gamma production in human dendritic cells via triggering of TLR2.

  2006cited by this paper
• Mycobacteria Induce IFN-γ Production in Human Dendritic Cells via Triggering of TLR21

  2006cited by this paper
• Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.

  2006cited by this paper
• Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.

  2005cited by this paper
• ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis

  2005cited by this paper
• Cytokines in cancer pathogenesis and cancer therapy

  2004cited by this paper
• Cytokines in cancer immunity and immunotherapy

  2004cited by this paper
• Serum tumor markers in the management of ovarian, endometrial and cervical cancer.

  2004cited by this paper
• Molecular mechanisms regulating Th1 immune responses.

  2003cited by this paper
• Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.

  2003cited by this paper
• IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside

  2002cited by this paper
• Interleukin-12 in anti-tumor immunity and immunotherapy.

  2002cited by this paper
• Natural killer cells and dendritic cells: rendezvous in abused tissues

  2002cited by this paper
• Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu.

  2001cited by this paper
• A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

  2000cited by this paper
• IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells

  2000cited by this paper
• Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

  2000cited by this paper
• The costimulatory effect of IL‐18 on the induction of antigen‐specific IFN‐γ production by resting T cells is IL‐12 dependent and is mediated by up‐regulation of the IL‐12 receptor β2 subunit

  2000cited by this paper
• IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells.

  2000cited by this paper
• Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model

  1999cited by this paper
• Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration

  1999cited by this paper
• Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.

  1999cited by this paper
• IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

  1998cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells.

  1998cited by this paper
• IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.

  1998cited by this paper
• Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.

  1998cited by this paper
• A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.

  1997cited by this paper
• In vivo antitumor effects of murine interferon- γ -inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites

  1997cited by this paper
• IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12.

  1997cited by this paper
• Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

  1997cited by this paper
• Cellular responses to interferon-gamma.

  1997cited by this paper
• Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

  1997cited by this paper
• IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.

  1996cited by this paper
• Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells.

  1996cited by this paper
• Sciencescope.

  1995cited by this paper
• Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung

  1995cited by this paper
• SCIENCESCOPE

  1995cited by this paper
• A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock

  1995cited by this paper
• Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice

  1993cited by this paper

• Co-delivery of IL-12/IL-15/IL-18 engineered DC vaccines with anti-IL-10R and nanoconjugated methotrexate in melanoma

  2026cites this paper
• The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies.

  2025cites this paper
• Unlocking IL-18: A hidden key in cancer immunity.

  2025cites this paper
• Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems

  2025cites this paper
• Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18

  2024cites this paper
• Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses

  2024cites this paper
• Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy

  2024cites this paper
• Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy

  2024cites this paper
• Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies.

  2024cites this paper
• Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity

  2023cites this paper
• The Role of IL-18 in P2RX7-Mediated Antitumor Immunity

  2023cites this paper
• Engineered smart materials for RNA based molecular therapy to treat Glioblastoma

  2023cites this paper
• Research advances of clinical application of oncolytic viruses in treatment of gynecologic cancers.

  2023cites this paper
• SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy

  2023cites this paper
• Oncolytic virotherapy: basic principles, recent advances and future directions

  2023cites this paper
• Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

  2022cites this paper
• Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses

  2022cites this paper
• Liposomes in the Targeted Gene Therapy of Cancer: A Critical Review.

  2022cites this paper
• Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives.

  2022cites this paper
• Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis.

  2022cites this paper
• Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations

  2022cites this paper
• Oncolytic viruses and pancreatic cancer.

  2022cites this paper
• Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L

  2021cites this paper
• Gene Editing and Gene Therapies in Cancer Treatment

  2021cites this paper
• Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?

  2021cites this paper
• Virus-inspired Strategies for Cancer Therapy.

  2021cites this paper
• Current strategies in engaging oncolytic viruses with antitumor immunity

  2021cites this paper
• The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma

  2021cites this paper
• Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.

  2021cites this paper
• Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

  2021cites this paper
• Cytokines in oncolytic virotherapy.

  2020cites this paper
• Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice

  2020cites this paper
• Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency

  2020cites this paper
• Oncolytic Adenovirus in Cancer Immunotherapy

  2020cites this paper
• Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor

  2020cites this paper
• Externally-Controlled Systems for Immunotherapy: From Bench to Bedside

  2020cites this paper
• The two-faces of NK cells in oncolytic virotherapy.

  2020cites this paper
• Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

  2020cites this paper
• Recent advances in the development of gene delivery systems

  2019cites this paper
• IL-1 Family Members in Cancer; Two Sides to Every Story

  2019influential citation
• Interleukin-12 elicits a non-canonical response in B16 melanoma cells to enhance survival

  2019cites this paper
• Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

  2019cites this paper
• Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks

  2019cites this paper
• Oncolytic viruses: overcoming translational challenges

  2019cites this paper
• Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors

  2019cites this paper
• Synergistic combination of oncolytic virotherapy with CAR T-cell therapy.

  2019cites this paper
• Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

  2019cites this paper
• Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer

  2019cites this paper
• Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma

  2019cites this paper
• New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

  2018cites this paper
• Please stand by: how oncolytic viruses impact bystander cells.

  2018cites this paper
• Armed oncolytic viruses: A kick-start for anti-tumor immunity

  2018cites this paper
• Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

  2018cites this paper
• Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model

  2018cites this paper
• Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses

  2018cites this paper
• Advances in oncolytic adenovirus therapy for pancreatic cancer.

  2018cites this paper
• Optimized biodegradable polymeric reservoir‐mediated local and sustained co‐delivery of dendritic cells and oncolytic adenovirus co‐expressing IL‐12 and GM‐CSF for cancer immunotherapy

  2017cites this paper
• Interleukin-18: a regulator of cancer and autoimmune diseases

  2017cites this paper
• Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

  2017cites this paper
• Targeting Melanoma with Cancer-Killing Viruses

  2017cites this paper
• Immune System, Friend or Foe of Oncolytic Virotherapy?

  2017cites this paper
• Designing and building oncolytic viruses

  2017cites this paper
• Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development

  2017cites this paper
• Prospects for combined use of oncolytic viruses and CAR T-cells

  2017cites this paper
• THE PRECLINICAL DEVELOPMENT OF ONCOLYTIC VIRAL IMMUNOTHERAPY FOR EPITHELIAL CANCER

  2017cites this paper
• Oncolytic virotherapy : the story so far

  2017cites this paper
• Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.

  2016cites this paper
• Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy

  2016cites this paper
• Antitumor Effects of IL-12 in Preclinical Studies

  2016cites this paper
• Promising Immunotherapeutic Approaches in Clinical Trials

  2016cites this paper
• Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology

  2016cites this paper
• Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine

  2016cites this paper
• Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model

  2016cites this paper
• Oncolytic Immunotherapy for Treatment of Cancer.

  2016cites this paper
• Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy

  2016cites this paper
• From Benchtop to Bedside: A Review of Oncolytic Virotherapy

  2016cites this paper
• Oncolytic viruses—immunotherapeutics on the rise

  2016cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

  2016cites this paper
• Cancer immunotherapy: the beginning of the end of cancer?

  2016cites this paper
• Corrigendum to "T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses".

  2016cites this paper
• Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts

  2016cites this paper
• Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy

  2016cites this paper
• Cancer Gene Therapy

  2015cites this paper
• T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

  2015cites this paper
• Role of NK cells in immunotherapy and virotherapy of solid tumors.

  2015cites this paper
• Tissue Specific Promoters in Colorectal Cancer

  2015cites this paper
• Emerging role of Natural killer cells in oncolytic virotherapy

  2015cites this paper
• Del-1 overexpression potentiates lung cancer cell proliferation and invasion.

  2015cites this paper
• Context‐dependent role of IL‐18 in cancer biology and counter‐regulation by IL‐18BP

  2015cites this paper
• Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer

  2014cites this paper
• A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model

  2014cites this paper
• Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects

  2014cites this paper
• Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intratumoral Injection of Adenovirus Vector or Vector-Transduced Dendritic Cells

  2014cites this paper
• Going viral with cancer immunotherapy

  2014cites this paper
• Evolution of oncolytic viruses: novel strategies for cancer treatment.

  2013cites this paper
• Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy

  2013cites this paper
• Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers

  2013cites this paper
• Oncolytic Adenovirus Expressing IL-23 and p35 Elicits IFN-γ- and TNF-α-Co-Producing T Cell-Mediated Antitumor Immunity

  2013cites this paper
• Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

  2013cites this paper